Cipla Targets Global Respiratory Biosimilars With Kemwell JV

Indian Firm Will Bring Its ‘Respiratory Prowess’ To Planned Venture

 
• By Dean Rudge
  
Start Launch
Cipla is to hold a 60% stake in the JV • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products